OLD Point Trust & Financial Services NA reduced its stake in Johnson & Johnson stock (NYSE: JNJ – Get Rating) by 0.8% in Q1, according to its latest 13F filing with the Securities and Exchange Commission (SEC) . The institutional investor held 51,836 shares of the company after selling 432 shares during the quarter. Johnson & Johnson represents 3.8% of OLD Point Trust & Financial Services NA’s holdings, making it its 8th largest holding. OLD Point Trust & Financial Services NA’s holdings in Johnson & Johnson were worth $9,187,000 when it was last filed with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also been buying and selling shares of the company recently. Family CFO Inc acquired a new position in Johnson & Johnson stock during Q4 worth approximately $26,000. Steward Financial Group LLC acquired a new position in Johnson & Johnson stock during Q4 worth approximately $34,000. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson stock during Q1 worth approximately $38,000. Advocacy Wealth Management Services LLC increased its position in Johnson & Johnson shares by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after acquiring 67 additional shares last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in Johnson & Johnson stock during Q4 worth approximately $49,000. 68.78% of the shares are held by institutional investors and hedge funds.
Wall Street analysts predict growth
Several research companies have recently published reports on JNJ. Wells Fargo & Company raised its price target on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 research report. UBS Group cut its target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday. Raymond James raised his target price on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a Wednesday, April 20 report. Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a Tuesday, April 12 report. Finally, SVB Leerink reduced its target price on Johnson & Johnson from $200.00 to $194.00 in a report released on Wednesday. Four analysts gave the stock a hold rating, six issued a buy rating and one gave the company a strong buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.
Johnson & Johnson Stock up 0.5%
JNJ opened at $172.12 on Friday. The company has a 50-day moving average price of $176.25 and a two-hundred-day moving average price of $174.35. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt ratio of 0.39. The company has a market capitalization of $452.92 billion, a PE ratio of 25.05, a P/E/G ratio of 3.48 and a beta of 0.63. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.
Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released quarterly earnings data on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The company’s revenues increased by 3.0% compared to the same quarter last year. During the same period of the previous year, the company achieved EPS of $2.48. As a group, research analysts expect Johnson & Johnson to post EPS of 10.02 for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Monday, August 22. Johnson & Johnson’s dividend payout ratio (DPR) is 65.79%.
Insider Trading at Johnson & Johnson
In other news, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade that took place on Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a document filed with the SEC, accessible via this link. In related news, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. As a result of the sale, the chief accountant now owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the SEC, accessible via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction that took place on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The disclosure of this sale can be found here. Insiders of the company own 0.35% of the shares of the company.
Johnson & Johnson Profile
(Get an evaluation)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.